Oncology Meets Immunology: The Cancer-Immunity Cycle

• p. 1 Introduction, third paragraph

  human cancer have demonstrated that overcoming negative

Only the authors can say what is right here.

Judge's note: Checked the crop of p1. Read literally, the sentence says that overcoming the negative regulators explains the failure of protection. The rest of the paper says the regulators cause the failure and that overcoming them restores immunity. The wording is garbled and the authors should reword it.

Second check: another model agreed

• p. 5 T Cell Priming and Activation, second paragraph

  enhancing both antitumor immune responses and autoimmune

• p. 5 T Cell Priming and Activation, second paragraph

  enhancing both antitumor immune responses and autoimmune toxicity

Only the authors can say what is right here.

Judge's note: Checked the p5 crop. The preceding sentence argues for less autoimmune-related toxicity, so this wording misdescribes what is evidently meant. It is a wording issue only.

Second check: another model agreed

• p. 3 Figure 2 legend, abbreviations

  ICAM1, intracellular

• p. 3 Figure 2 legend

  intracellular

• p. 3 Figure 2 legend, abbreviations

  ICAM1, intracellular adhesion molecule 1

Only the authors can say what is right here.

Judge's note: Rests on outside knowledge: ICAM1 is the standard abbreviation for intercellular adhesion molecule 1. The page image of the Figure 2 legend on p3 reads 'intracellular', so this is not an extraction artefact.

Second check: none (judge only)

• p. 3 Figure 2 legend, abbreviations

  cytotoxic T-lympocyte

• p. 3 Figure 2 legend

  ICAM1, intracellular

• p. 3 Figure 2 legend

  T-lympocyte

Judge's note: The page image of the Figure 2 legend on p3 shows 'T-lympocyte'. The same legend spells 'B- and T-lymphocyte' correctly later on. The ICAM1 point raised in some notes is handled under C002.

Second check: none (judge only)

• p. 3 Figure 2 legend

  factors, such as PD-L1, can have an inhibitory function

Judge's note: Checked the legend in the p3 crop. As printed the sentence is ungrammatical.

Second check: none (judge only)

• p. 3 Right column, last line

  and mass spectroscopy of peptides eluted from MHCI molecules

• p. 9 Reference list, Kasuga (2013)

  immunoaffinity-mass spectrometry

Judge's note: Checked the p3 crop and the reference list on p9. The terms are often used loosely, so this is a minor terminology point.

Second check: none (judge only)

• p. 4 Table 1, step 1, (−) Inhibitors

  Tolergenic or apoptotic

• p. 3 Figure 2, step 1 box

  Tolergenic cell death

Judge's note: The Table 1 crop on p4 and the Figure 2 box on p3 (visible in the C004 and C007 crops) both show 'Tolergenic'.

Second check: none (judge only)

• p. 4 Table 1, step 7, (−) Inhibitors

  MICA:MICB

• p. 3 Figure 2, step 7 box

  MICA/MICB

Judge's note: Checked the Table 1 crop on p4 and Figure 2 on p3. The paper's notation is mixed: Table 1 also writes CD40L/CD40, and Figure 2 writes PD-L1/PD-1. So this is a minor notation inconsistency rather than a clear error.

Second check: none (judge only)

• p. 5 T Cell Priming and Activation, second paragraph

  modulate complimentary steps on the Cancer-Immunity Cy-

• p. 5 T Cell Priming and Activation, second paragraph

  that modulate complimentary steps on the Cancer-Immunity Cy-

• p. 5 T Cell Priming and Activation

  complimentary steps on the Cancer-Immunity Cy-

Judge's note: The p5 page image confirms 'complimentary'. This is a word-choice error.

Second check: none (judge only)

• p. 5 Bypassing Vaccination by Adoptive T Cell Therapy, first sentence

  Another exciting development is that the initial demonstrations

Judge's note: Checked the opening of the adoptive T cell therapy section on p5. The sentence is grammatically incomplete.

Second check: none (judge only)

• p. 5 Immunostat Blockade paragraph

  MPDL3280A (anti-PDL1; Genentech/Roche

• p. 5 Immunostat Blockade paragraph vs Table 2

  Bristol Myers Squibb

Judge's note: The p5 crop shows both forms. The text layer has 'anti-PD-L1 antibody' later in the text and 'Bristol-Myers' in Table 2. The inconsistency is cosmetic.

Second check: none (judge only)

• p. 7 Concluding Remarks, first paragraph

  of systemic factors can effect or contribute to the success or fail-

• p. 7 Concluding Remarks

  can effect or contribute to the success or fail-

Judge's note: Checked the p7 crop. Both grammatical errors are visible on the page image.

Second check: none (judge only)

• p. 7 Combination Immune Therapies

  may be completing the defect in the Cancer-Immunity Cycle

• p. 7

  completing the defect in the Cancer-Immunity Cycle

Only the authors can say what is right here.

Judge's note: The page image (p7, left column) confirms the wording. 'Completing a defect' does not make sense in context, since the text means that CTLA4 blockade makes up for a broken step (steps 1-6). 'complementing' or 'correcting' is the likely intended word. Only the authors can say which they meant, so this is an author query.

Second check: none (judge only)

• p. 7 Combination Immune Therapies

  Further studies of preipilimumab and on ipilimumab

Judge's note: The page image confirms 'preipilimumab' is printed as one word in mid-line, so this is not a line-break artefact. 'on ipilimumab' is the 'on-treatment' modifier, not a mismatched preposition, so the reviewer's point about 'of ... and on' does not hold. What remains is the missing hyphenation of the paired compound modifiers. This is cosmetic.

Second check: none (judge only)

• p. 9 References, Powderly et al. 2013

  Gettlinger, S.N.

• p. 10 References, Spigel et al. 2013

  Gettinger, S.N.

Judge's note: The p9 crop shows 'Gettlinger, S.N.' in Powderly et al. The p10 crop shows 'Gettinger, S.N.' in Spigel et al. and 'Get-tinger, S.N.' in Topalian 2013. Topalian 2012b also has 'Gettinger, S.N.'. The spelling differs within the paper's own reference list.

Second check: none (judge only)

• p. 10 References, Wang et al. 2013

  Immune evasion evasion of mantle cell lymphoma

• p. 10

  Li, Y., et al. (2013). Immune evasion evasion of mantle cell lymp

Judge's note: The p10 crop (right column, Wang et al. entry) shows 'evasion evasion' printed twice in the page image. It is not an extraction artefact.

Second check: code check

• p. 10 References, Wolchok et al. 2013

  mab plus ipilimumab in advanced melanoma. N. Engl. J. Med.

Only the authors can say what is right here.

Judge's note: The p10 crop confirms the entry ends at the journal name. Other online-ahead-of-print entries in the same list give 'Published online <date>' and a DOI: Hamid 2013a (NEJM, June 2, 2013), Wang 2013 (March 18, 2013) and a Clin. Lung Cancer entry (June 19, 2013). So the Wolchok entry is inconsistent with the list's own style. The missing details cannot be filled in from the files, so this goes to the authors.

Second check: none (judge only)